Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elaprase phase IV study in Indian pediatric and adult patients with Hunter syndrome
2022-004193-39Phase 4
- Sponsor
- Takeda
- Start
- Dec 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of idursulfase in mucopolysaccharidosis type 2, sponsored by Takeda. Primary endpoint: Safety.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2022-004193-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004193-39.